Bilateral anterior uveitis after immunotherapy for malignant melanoma

Immune checkpoint blockade therapy is relatively a new treatment for cancer which has shown promising results. However, immune-related side effects including uveitis have occasionally been reported during this therapy. Herein, we report the case of a 65-year-old male who suffered bilateral anterior...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Chia-Jui, Chen, Shih-Jen, Hwang, De-Kuang, Liu, Catherine Jui-Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169330/
https://www.ncbi.nlm.nih.gov/pubmed/30294532
http://dx.doi.org/10.4103/tjo.tjo_88_17
Descripción
Sumario:Immune checkpoint blockade therapy is relatively a new treatment for cancer which has shown promising results. However, immune-related side effects including uveitis have occasionally been reported during this therapy. Herein, we report the case of a 65-year-old male who suffered bilateral anterior uveitis after immune checkpoint blockade therapy with pembrolizumab and ipilimumab for malignant melanoma. His symptoms and signs improved after topical treatment with corticosteroids. Clinicians should be aware that uveitis can be an immune-related adverse event of immunotherapy.

Ejemplares similares